Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of SPARC1613 vs Reference1613 in Breast Cancer
NCT03109249Phase 1Completed
- Sponsor
- Sun Pharma
- Start
- Jan 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of SPARC1613 in breast cancer (2 arms), sponsored by Sun Pharma. Primary endpoint: Maximum observed concentration. Started Jan 2017; status: completed.
02
Drugs
SPARC1613
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03109249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03109249.